| P2093 | author name string | G David Roodman | |
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | Metastatic bone disease: clinical features, pathophysiology and treatment strategies | Q28202792 |
| | The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma | Q28236113 |
| | RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis | Q28294501 |
| | Metastasis to bone: causes, consequences and therapeutic opportunities | Q29614310 |
| | Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation | Q30441987 |
| | Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand | Q30670375 |
| | A molecular compendium of genes expressed in multiple myeloma | Q31105650 |
| | Cloning and characterization of the annexin II receptor on human marrow stromal cells | Q33253275 |
| | Cell biology of the osteoclast | Q33700885 |
| | Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease | Q33740176 |
| | The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. | Q33823576 |
| | TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development | Q33834762 |
| | Molecular mechanisms of osteolytic bone metastases | Q33909842 |
| | Role of endothelin-1 in osteoblastic bone metastases | Q33963981 |
| | Mechanisms of bone metastasis | Q33977526 |
| | Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases | Q34086847 |
| | Management of bone metastases | Q34100900 |
| | Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo | Q34224284 |
| | Annexins--unique membrane binding proteins with diverse functions | Q34323662 |
| | Novel therapies targeting the myeloma cell and its bone marrow microenvironment | Q34461557 |
| | Transcription factors in bone: developmental and pathological aspects | Q34735288 |
| | Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease | Q35631319 |
| | Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo | Q35642745 |
| | Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin | Q35683618 |
| | Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment | Q35802226 |
| | MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. | Q36141697 |
| | Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease | Q36169814 |
| | RANKing intracellular signaling in osteoclasts | Q36191485 |
| | TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. | Q36404187 |
| | Role of decorin in the antimyeloma effects of osteoblasts | Q36732801 |
| | Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? | Q37219226 |
| | Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma | Q37271048 |
| | Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis | Q37360238 |
| | Osteoclasts are important for bone angiogenesis | Q37706007 |
| | Sclerostin: a gem from the genome leads to bone-building antibodies | Q37766538 |
| | Osteoblast function in myeloma | Q37769965 |
| | Tumor-host cell interactions in the bone disease of myeloma | Q37771082 |
| | Advances in the biology and treatment of bone disease in multiple myeloma | Q37853737 |
| | Parathyroid hormone related protein (PTHrP) in tumor progression | Q37929046 |
| | Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation | Q38325516 |
| | Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone | Q39116021 |
| | Sclerostin is overexpressed by plasma cells from multiple myeloma patients | Q39443327 |
| | Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer | Q39534721 |
| | Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo | Q39695455 |
| | Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis | Q39730235 |
| | RUNX2 regulates the effects of TNFalpha on proliferation and apoptosis in SaOs-2 cells | Q39755402 |
| | The effect of timing in the administration of hepatocyte growth factor to modulate BMP-2-induced osteoblast differentiation. | Q39774810 |
| | Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma | Q39827635 |
| | Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis | Q40038407 |
| | Regulation of cancer cell migration and bone metastasis by RANKL. | Q40298349 |
| | Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism | Q40372846 |
| | IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma | Q40425654 |
| | MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. | Q40454635 |
| | Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain | Q40549071 |
| | IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells | Q40616669 |
| | Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells | Q40728134 |
| | Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens | Q40762950 |
| | Annexin II tetramer: structure and function | Q40950533 |
| | Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice | Q40975330 |
| | Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study | Q41904942 |
| | Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation | Q42219222 |
| | Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study | Q42829926 |
| | Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastases | Q43011355 |
| | Tumor necrosis factor inhibits mesenchymal stem cell differentiation into osteoblasts via the ubiquitin E3 ligase Wwp1. | Q43095887 |
| | A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys | Q43192115 |
| | Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial | Q44611376 |
| | Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. | Q46283393 |
| | Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease | Q48022318 |
| | Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. | Q51054343 |
| | PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. | Q52942846 |
| | The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. | Q53621774 |
| | Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. | Q54535173 |
| | Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma | Q57904674 |
| P433 | issue | 3-4 | |
| P304 | page(s) | 569-578 | |
| P577 | publication date | 2012-12-01 | |
| P1433 | published in | Cancer and Metastasis Reviews | Q2647982 |
| P1476 | title | Genes associate with abnormal bone cell activity in bone metastasis | |
| P478 | volume | 31 | |